Stay updated on SubQ Pertuzumab/Trastuzumab Preference in Early Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the SubQ Pertuzumab/Trastuzumab Preference in Early Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SubQ Pertuzumab/Trastuzumab Preference in Early Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value Revision: v2.8.0 has recently changed to Revision: v2.8.1. This change likely represents an update or modification to the content or features of the webpage.
    Difference
    0.0%
    Check dated 2024-06-13T21:36:53.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 on the webpage has recently changed to 8. This change represents an update in the study details related to patient preference and satisfaction of subcutaneous administration of the fixed-dose combination of Pertuzumab and Trastuzumab in participants with HER2-positive early breast cancer.
    Difference
    0.0%
    Check dated 2024-06-06T14:28:53.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 6 to 7, indicating an update in the number of cycles or phases in a medical study related to healthcare publications. This change likely reflects an extension or modification in the study's timeline or protocol.
    Difference
    0.0%
    Check dated 2024-05-22T20:56:21.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Summary
    The change on the webpage possibly concerns Medical and healthcare-related publications and documentation.
    Difference
    2%
    Check dated 2024-05-01T18:56:44.000Z thumbnail image

Stay in the know with updates to SubQ Pertuzumab/Trastuzumab Preference in Early Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SubQ Pertuzumab/Trastuzumab Preference in Early Breast Cancer Clinical Trial page.